Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO + Hetrombopag + CsA for Transfusion-Dependent Non-Severe Aplastic Anemia
NCT06004791Phase 4Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human thrombopoietin in aplastic anemia (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 3 months. Status: unknown.
02
Drugs
recombinant human thrombopoietin
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06004791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004791.